GLP-1 and arterial inflammation — March 2026

From the other side of the consultation, briefly.

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

15 months later: down 62 lbs, off lisinopril, A1C from 8.4% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

anders_CPH said:

I want to bring up the cardiovascular angle on cardiovascular risk.

6 month update on cardiovascular risk: down 51 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

anders_CPH said:

I want to bring up the cardiovascular angle on cardiovascular risk.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

Following on from anders_CPH — and this may be the naive question:

What did you change at the same time, and can you separate the two now?

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.